| Prev Close | 622.45 |
| Open | 635.00 |
| Day Low/High | 623.50 / 639.00 |
| 52 Wk Low/High | 271.37 / 646.33 |
| Volume | 1.04M |
| Avg Volume | 1.36M |
Regeneron Pharmaceuticals Inc. (REGN)
627.25
4.80
0.77
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 110.67M |
| Market Cap | 70.04B |
| EPS | 19.40 |
| P/E Ratio | 31.28 |
| Div & Yield | N.A. (N.A) |
Double Top Could Spell Double Trouble for Regeneron
The biopharmaceutical company is in for a deeper bear phase.
Cramer: This Is Where I Say I Was Wrong
My speculation on Fitbit and Alcoa didn't work out.
Jim Cramer Says Own Salesforce.com, Regeneron, First Solar
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.
Have a CIGAR, You'll Go Far in 2016
5 biotech stocks that could outperform the overall market in 2016.
Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE
TheStreet looked at stocks that soared under the Federal Reserve’s QE program, and Jim Cramer explains why some shares performed better than others.
Don't Abandon the Biotech Ship
There's too much good out there.
Ailing Stocks Are Making a Recovery
Apple tops the list, but it has lots of company.
Jim Cramer Sees a Deal on Priceline Stock, Likes Weyerhaeuser
TheStreet's Jim Cramer said to buy Priceline (PCLN) on the dip Monday while answering viewer questions from the floor of the New York Stock Exchange.
This Acronym Really Stinks
Don't use it as a gauge of market strength.
Stocks Slightly Lower Amid Yellen's Rate-Hike Hints
Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...
Rotation Is Enough to Make Your Head Spin
Bad news isn't always a bad thing.
Anatomy of a Rally: Simpler Than You Think
Understanding why stocks act the way they do.
Grasping at Growth: The Hunt Is On
Once again, buyers are going for the gusto.
5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher
The common thread in these 5 names is the bullish divergence between the lower lows in price and the higher low in the momentum study.
Regeneron Has More Upside to Go
The stock shows bullish momentum and could climb 5%.
We're Feeling Better About Growth Stocks
Amazon is among the indicators.
Eli Lilly's Stock Is Worth a Chance Below $80
The company's stock will likely be among the first to turn.
Plenty of Good News -- If You Look
Not all growth is hated today.
Drug Stocks' Earnings Power Won't Go Away
Before you sell them, ask yourself at what multiple you sell.
Jim Cramer: Could Glencore Be the Next Long Term Capital?
Jim Cramer answered viewers’ Twitter (TWTR) questions from the floor of the Stock Exchange and said he's not assuaged by Glencore's (GLCNF) comments that it is ‘operationally and financially robust.'
These Biotech Trades are a Great Rx
Hillary Clinton has created some good short-term opportunities.
It May Be Early, but Check Out the Moves in These Stocks
High-growth, REIT and consumer names clearly want to go higher.
Regeneron Chart Looks Rejuvenated
Shares appear ready to return to previous highs.
Not the Kind of Waves You Want to Make
On days like this, bizarre action is the norm.
It's OK, Market: Some (But Not All) Is Forgiven
But this might be a good time to sell.
This Volatility in the Indices Is Just Plain Phony
It's just machine to machine, but we are haunted by 2008.
Build a Core Position in Biotech Intrexon at These Lower Prices
Following a 40% decline, now looks good for scaling into the stock.
Even Stocks With Bullish Outlooks Are Not Safe in the Market Carnage
Which means interest rate hikes are being built into prices.
